{"id":"en3267","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL596","moleculeType":"Small molecule","molecularWeight":"336.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EN3267 selectively inhibits the C5a receptor (C5aR1), a key component of the complement cascade that drives innate immune activation and inflammation. By blocking C5a signaling, the drug reduces chemotaxis and activation of neutrophils and other immune cells, thereby dampening excessive inflammatory responses. This mechanism is intended to treat complement-mediated inflammatory and autoimmune diseases.","oneSentence":"EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:47.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immunoglobulin A nephropathy (IgAN)"}]},"trialDetails":[{"nctId":"NCT00263575","phase":"PHASE3","title":"Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2005-12","conditions":"Pain, Cancer","enrollment":139},{"nctId":"NCT00262678","phase":"PHASE3","title":"Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2005-12","conditions":"Pain, Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fentanyl"],"phase":"phase_3","status":"active","brandName":"EN3267","genericName":"EN3267","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation. Used for Immunoglobulin A nephropathy (IgAN).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}